neuroClues Certified To Solve Neurodegenerative Mysteries With Eye-Tracking Device
By Gabrielle Mostello
French-Belgian company neuroClues announced on Tuesday that it secured CE certification for its AI-powered eye-tracking device, which uses visual movements as biomarkers for neurological conditions. Equipped with a CE mark, neuroClues is poised to deploy its technology in hospitals and clinics across Europe, initially targeting neurologists, movement disorder specialists and neuro-ophthalmologists.
“neuroClues’ introduction to the EU market will improve diagnosis and care pathways for millions of EU patients, bringing objectivity to current clinical practice,” said neuroClues CEO and co-founder Antoine Pouppez. “This represents a significant value inflection point in our mission to improve neurodegenerative disease diagnosis.”
The European medtech seeks to improve the diagnosis of neurological disorders, which at present can be a long and arduous process. These diagnostic delays can have a sizable impact on patients’ health and neurological state, according to the company.
neuroClues’ solution works in tandem with existing diagnostic methods by identifying biomarkers for neurodegenerative diseases with a portable and lightweight device that is placed over a patient’s eyes. The hardware presents visual stimuli and records the eye movements that it triggers. neuroClues’ device is accompanied by an app where providers can access the diagnostic protocol, and receive live feedback and assistance for interpreting results.
According to neuroClues, the device can identify a variety of neurodegenerative conditions, including Parkinson’s diseases, progressive supra nuclear palsy, multiple system atrophy, cerebellar ataxia, Alzheimer’s disease, dementia and multiple sclerosis.
Strategic research partnerships
neuroClues has established research partnerships with groups in Europe and North America to advance its mission and hone its product. A study at the Paris Brain Institute is currently enrolling dozens of participants per week, and research will commence shortly at two major US institutions involving hundreds of patients with movement disorders.
Other collaborations are in the works; neuroClues is in discussions with the Constances Mega-Cohort to integrate eye movement testing into their research for participants aged 55 years or older. The project seeks to establish a comprehensive database of eye movement biomarkers, enabling earlier and more accurate diagnoses of neurodegenerative disorders.
Future growth in mind
Along with the CE mark announcement, neuroClues shared that it has appointed former Medtronic executive Bart Stulens as chief commercial officer. “neuroClues’ mission to ‘develop the stethoscope of the brain’ and revolutionise neurologic care through early diagnosis aligns perfectly with my passion for driving innovation in healthcare,” Stulens said, adding that he looks forward to supporting the company’s growth during this “pivotal moment.”
The company also announced plans to close a €10-million(US$10.4million) series A in the first half of 2025, two-thirds of which is currently soft-committed by existing investors. With these funds, neuroClues plan to grow its commercial team and bring its product to the European market.
neuroClues last raised €5 million to launch its technology in April, having raised a total of €12 million since its inception in 2020.
